GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

Related Keywords

United States ,Melnikov Dmitriy ,Receptor Agonists For Weight Loss Research ,Weight Loss ,Image Credit ,Pharmetrics Plus ,Antagonist ,Glp 1 ,Alcohol ,Flood ,Bupropion ,Diabetes ,Drugs ,Wood ,Gastroparesis ,Glucagon ,Glucagon Like Peptide 1 ,Glucose ,Ormone ,Hyperlipidemia ,Muscle ,Naltrexone ,Pancreatitis ,Eceptor ,Research ,Smoking ,